Skip to NavigationSkip to content

ViiV Healthcare announces authorisation of Europe's first long-acting HIV injection

Published on 21/12/20 at 09:02am
Image credit: Viiv Healthcare

ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline, has announced the authorisation of Europe’s first complete long-acting injectable HIV treatment.

Marketing Authorisation is based on the pivotal Phase III ATLAS (Antiretroviral Therapy as Long-Acting Suppression), FLAIR (First Long-Acting Injectable Regimen) and ATLAS-2M studies, which included more than 1,200 participants from 16 countries. In the newly authorised treatment of HIV-1 infection in adults who are virologically suppressed, ViiV’s Cabotegravir and Janssen’s rilpivirine are co-administered as two intramuscular injections at the same appointment.

This authorisation means that for the first time, people living with HIV in Europe may be able to receive a long-acting injectable treatment instead of taking daily oral tablets – the new treatment makes it possible for them to reduce the days they receive treatment from 365 to just 12 or 6 per year.

The largest global HIV patient-reported outcomes study to date, conducted by ViiV Healthcare, found that when participants were asked about their treatment aspirations and attitudes towards innovative medications, 55% would prefer not having to take medication every day, as long as their HIV stays suppressed. In addition, 58% noted that taking daily HIV medication acts as a constant reminder of HIV in their lives, while up to 38% of participants reported anxiety around the fact that taking daily treatment could increase the chances of revealing their HIV status to others.

Deborah Waterhouse, CEO of ViiV Healthcare, said: “We push the boundaries to provide new treatment options that will help make a difference to people’s lives. We saw from the patient reported outcomes in our pivotal clinical trials that approximately 9 out of 10 people who switched to the long-acting regimen preferred this over their previous daily oral tablets.

“It will potentially change the treatment experience for some people living with HIV by removing the need for daily HIV tablets. We are committed to pursuing innovative research to meet the diverse needs of the HIV community, and we won’t stop until we have more ways to treat, and hopefully one day cure, HIV.”

Darcy Jimenez

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches